CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T cells) are a promising new treatment for cancer, but are associated with unique toxicities. Here, the authors test CAR-T-cell-derived exosomes as a surrogate for CAR-T cells and show that they can elicit a potent antitumour...
Guardado en:
Autores principales: | Wenyan Fu, Changhai Lei, Shuowu Liu, Yingshu Cui, Chuqi Wang, Kewen Qian, Tian Li, Yafeng Shen, Xiaoyan Fan, Fangxing Lin, Min Ding, Mingzhu Pan, Xuting Ye, Yongji Yang, Shi Hu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9922d9f362cb422ca19401f860eaed83 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Yao Wang, et al.
Publicado: (2021) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021) - Car and driver
-
CAR T-CELL
por: Francesco Saglio
Publicado: (2021) - Centro azu ́car